Table 1.
Baseline demographic, clinical, cognitive characteristics
| Characteristic | Active/Placebo (n = 20) | Placebo/Active (n = 19) | P-value |
|---|---|---|---|
| Demographics | |||
| Age, years | 69.6 ± 5.65 | 71.1 ± 8.04 | 0.50 |
| Male gender, n (%) | 10 (50.0) | 11 (57.9) | 0.62 |
| Race, n (%) | 0.32 | ||
| White | 20 (100.0) | 19 (100.0) | |
| Hispanic, n (%) | 1 (5.0) | 0 | |
| Education, years | 16.2 ± 2.95 | 16.4 ± 2.65 | 0.81 |
| Married, n (%) | 19 (95.0) | 18 (94.7) | 0.97 |
| Clinical Features | |||
| CDR (global score), median (Q25–Q75) | 0.5 (0.5–0.5) | 0.5 (0.5–0.5) | 0.33 |
| CDR (sum of boxes), median (Q25—Q75) | 1.0 (1.0–2.0) | 1.5 (1.0–2.5) | 0.35 |
| MCI subtype, n (%) | 0.94 | ||
| Amnestic | 19 (95.0) | 17 (94.4) | |
| Multi-domain | 1 (5.0) | 1 (5.6) | |
| APOE4 status, n (%) | 0.99 | ||
| Homozygous APOE4 | 7 (35.0) | 7 (36.8) | |
| Heterozygous APOE4 | 11 (55.0) | 10 (52.6) | |
| No APOE4 alleles | 2 (10.0) | 2 (10.5) | |
| Body mass index, kg/m2 | 25.3 ± 3.69 | 24.5 ± 3.56 | 0.53 |
| Neuropsychological measures, median (Q25—Q75) | |||
| MoCA | 21.0 (19.0–23.0) | 21.0 (19.0–24.0) | 0.79 |
| ADAS-Cog 11 | 9.0 (7.0–12.0) | 11.0 (9.0–16.0) | 0.28 |
| ADAS-Cog 13 | 17.5 (14.5–20.5) | 18.0 (15.0–24.0) | 0.46 |
| Trails A (s) | 32.0 (27.5–45.0) | 34.0 (27.0–43.0) | 0.78 |
| Trails B (s) | 92.0 (57.5–162) | 96.5 (73.0–146) | 0.93 |
| Clock | 5.0 (4.0–5.0) | 5.0 (4.0–5.0) | 0.37 |
| Logical memory | 6.5 (4.0–9.5) | 7.0 (4.0–10.0) | 0.71 |
| Delayed recall | 3.0 (0.5–6.0) | 4.0 (0.0–6.0) | 0.77 |
| Animal fluency | 15.5 (11.5–18.0) | 14.0 (12.0–19.0) | 0.87 |
| Boston naming | 26.5 (24.0–28.0) | 26.0 (23.0–29.0) | 0.95 |
| NPI | 1.0 (0.0–6.0) | 2.0 (0.0–8.0) | 0.87 |
ADAS-Cog = Alzheimer’s Disease Assessment Scale–Cognitive Subscale; CDR = Clinical dementia rating; MoCA = Montreal Cognitive Assessment; NPI = Neuropsychiatric Inventory.